Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688475 · ClinicalTrials.gov registry record · Phase 1
A Rollover Study of CC-122
A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT05688475 is a Phase 1 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 12 participants, below the 152-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05688475, a Phase 1 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG CC-122
Study Locations (7)
Other
- Local Institution - 300 - Bordeaux
- Local Institution - 301 - Marseille
- Local Institution - 400 - Amsterdam
New York
- Local Institution - 100 - New York
Tennessee
- Local Institution - 101 - Nashville
Wisconsin
- Local Institution - 102 - Madison
Tokyo
- Local Institution - 500 - Koto-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05688475
The ClinicalTrials.gov registry entry for NCT05688475 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT05688475 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05688475 about?
NCT05688475 is a clinical study titled "A Rollover Study of CC-122". The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NC...
What is the current status of trial NCT05688475?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-04-11. Estimated completion is 2026-02-25.
What conditions does trial NCT05688475 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05688475?
The interventions under investigation include: Dexamethasone (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT05688475?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05688475 being conducted?
This trial has 7 study locations across New York, Tennessee, Wisconsin, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.